Severe Cardiomyopathy Induced by Adalimumab Administration for Crohn’s Disease

Case Report

Austin Cardio & Cardio & Cardiovasc Case Rep. 2020; 5(1): 1035.

Severe Cardiomyopathy Induced by Adalimumab Administration for Crohn’s Disease

Toufaily A1,2*

¹Division of Cardiology, Lebanese University, Faculty of Medical Sciences, Hadath, Lebanon

²Division of Cardiology, Rafik Hariri University Hospital, Beirut, Lebanon

*Corresponding author: Ali Toufaily, Division of Cardiology, Lebanese University, Faculty of Medical Sciences, Hadath, Lebanon. Division of Cardiology, Rafik Hariri University Hospital, Beirut, Lebanon

Received: January 06, 2020; Accepted: January 29, 2020; Published: February 05, 2020

Abstract

The use of tumor necrosis factor alpha inhibitors - anti-TNFa (infliximab, adalimumab, and certolizumab) in the treatment of Inflammatory Bowel Disease (IBD) provide a major therapeutic advance, allowing significant benefits in the induction and maintenance of remission in Crohn’s disease [1-3]. However, the safety-profile of TNF inhibitors with regard to worsening or new onset of heart failure is still very controversial. Consequently, there has been a lot of attention paid to the risk of cardiovascular side effects associated with adalimumab therapy [4-6].

A 42 year old woman treated with adalimumab for severe Crohn’s disease exacerbation; 8 days after the second dose of adalimumab (80mg), she presented with dramatic clinical features of heart failure and pulmonary edema. Echocardiography demonstrated severely depressed left ventricle contractility with ejection fraction 35%; cardiac MRI revealed no gadolinium enhancement (no ischemia, no myocarditis). Adalimumab was discontinued, and patient was treated with evidence-based oral disease-modifying HF therapy; 2 months later, cardiac function has returned to normal.

This case clearly demonstrated the acute onset of decompensated heart failure with adalimumab usage.

Keywords: Tnf-A Inhibitor; Adalimumab; Heart Failure; Crohn’s Disease

Introduction

Inhibitors of Tumor Necrosis Factor (TNF)-alpha (adalimumab) offer an important targeted therapy in a large number of inflammatory conditions, including Rheumatoid Arthritis (RA), psoriasis, spondyloarthritis and Inflammatory Bowel Disease (IBD) [7,8]. In fact , the effectiveness of those drugs has been well established; However, multiple adverse effects have been identified through both clinical trials and post-marketing surveillance, ranging from benign to serious side effect such as lymphomas, infections (especially reactivation of latent tuberculosis), demyelinating disease and cardiomyopathy, which are associated with substantial mortality [9,10].

Case Presentation

A 42 year old woman, former smoker, non alcoholic has been diagnosed with Crohn’s disease since teenage, maintained on azathioprine. Apart from her gastro-intestinal symptoms, her prior medical history were unremarkable. She was admitted to our ward for profuse watery diarrhea with abdominal pain, managed as acute exacerbation of her Crohn’s disease. At that time adalimumab 160mg was initiated and she had improved a lot from her baseline.

2 weeks later, she received a dose of 80mg subcutaneous injection according to the universal treatment regimen of adalimumab, then after 8 days, she presented to our ER department with severe shortness of breath, palpitation, cough, and desaturation.

Echocardiographic examination showed severe left ventricle function impairment with ejection fraction 35%, moderate mitral regurgitation with mild dilatation of LV cavity.

The laboratory findings showed elevated troponin, high pro BNP level, mild anemia, normal WBC count, normal TSH and D dimer levels.

Coronary angiography was made showing non stenotic coronaries (Figure 1).

Citation: Toufaily A. Severe Cardiomyopathy Induced by Adalimumab Administration for Crohn’s Disease. Austin Cardio & Cardiovasc Case Rep. 2020; 5(1): 1035.